Show notes
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good — J&J depression drug aces late-stage trial
The ugly — FDA delays review of Sanofi-Regeneron's Dupixent in COPD